Home / Resources / Strategic Leadership resources

薬事戦略

注目コンテンツ

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

ブログ

Upcoming strategic leadership webinars

ウェビナー

最適な投与量、最適な治療結果：Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

2026年4月23日 – 3-4pm (JST) and 10-11am (CET)

ウェビナー

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

2026年5月28日 – 3-4pm (JST) and 10-11am (CET)

Popular resources

お知らせ

Certara Welcomes Arjun Bedi to its Board of Directors 

お知らせ

Certara Near-Term Emissions Reduction Target Approved by Science Based Targets Initiative to Reduce Environmental Impact

ブログ

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

ウェビナー

Building Trust in Data – Transparency, Traceability, and the Human Element

論文

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

プレスリリース

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

以下のイベントで弊社のエキスパートをご紹介

展示会・学会

International PBPK Conference

April 21 - 24, 2026

展示会・学会

Asembia AXS26 Summit

April 26 - 30, 2026 – Las Vegas, NV

展示会・学会

ISPOR International Annual Conference 2026

May 17 - 20, 2026 – Philadelphia, PA

All Strategic Leadership resources

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Data Fabrics in Pharma: Connecting Data for Better Decisions

Certara Products, Certara.AI, Drug Development, Blog

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, New Approach Methodologies (NAMs), Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog

Building Trust in Data – Transparency, Traceability, and the Human Element

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Drug Development, Webinar

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Certara Services, Clinical Pharmacology, Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Conference

Marbach DDI Workshop 2026

Certara Products - Simcyp, Drug-Drug Interactions (DDI), Modeling and Simulation - PBPK, Conference

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Rare and Neglected Diseases, Blog

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

最適な投与量、最適な治療結果：Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。

薬事戦略

最新のリソース

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Data Fabrics in Pharma: Connecting Data for Better Decisions

注目コンテンツ

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Upcoming strategic leadership webinars

最適な投与量、最適な治療結果：Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Popular resources

Certara Welcomes Arjun Bedi to its Board of Directors

Certara Near-Term Emissions Reduction Target Approved by Science Based Targets Initiative to Reduce Environmental Impact

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Building Trust in Data – Transparency, Traceability, and the Human Element

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

以下のイベントで弊社のエキスパートをご紹介

International PBPK Conference

Asembia AXS26 Summit

ISPOR International Annual Conference 2026

All Strategic Leadership resources

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Data Fabrics in Pharma: Connecting Data for Better Decisions

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Building Trust in Data – Transparency, Traceability, and the Human Element

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Marbach DDI Workshop 2026

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

最適な投与量、最適な治療結果：Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

メルマガ登録

クイックアクセス

ソリューション

お問合せ